Form PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)				Attorney's Docket No. 39780-2830 P1C14		Application Serial No.			
				Applicant(s) Kevin P. BAKER, et al.					
				Filing Date: December 6, 2001	1	Group Art Unit: 1636			
	•		U.S.	PATENT DOCUMENTS	場際於於從				
Examiner Initials	Ref. No.	Date	Document No.	Name	Clas				
	<u> </u>						<u> </u>		
FOREIGN PATENT DOCUMENTS									
Examiner	Ref. No.	Date	Document No.	Name	Clas	Subclass	Translation		
Initials							YES	NO	
7.00 J	1.00 WAS 10 WAS		· · · · · · · · · · · · · · · · · · ·	THER DOCUMENTS	s, etc.)			() () () () () () () () () ()	
Examiner Initials	Initials No.								
Time	1.	No. 37, pp 26617-26624, September 10, 1999. Hanna, J.S., et al., "HER-2/neu Breat Cancer Predictive Testing", Oathology Associates Medical Laboratores - (1999). Hyman, E., et al., "Impact of DNA Amplification on Gene Expression Patterns in Breast Cancer ^{1,2} ", Cancer Research - 62:6240-6245 (2002). Mueller, Wendy M., et al., "Evidence That Glucose Metabolism Regulates Leptin Secretion from Cultured Rat Adipocytes", Endocrinology, Vol. 139, No. 2, pp 551-558 (1998).							
	2.								
	3.								
	4.								
	5.								
	6. Orntoft, T.F., et al., "Genome-wide Study of Gene Copy Numbers, Transcripts, and Protein Levels in Pa Invasive and Invasive Human Transitional Cell Carcinomas", Molecular & Cellular Proteomics - 1:37-4							f Non- 002).	
	7.	Pollack, J.R., et al., "Microarray Analysis Reveals a Major Direct Role of DNA Copy Number Alteration in the Transcriptional Program of Human Breast Tumors", PNAS – 99(20):12963-12968 (2002).							
	8.	Sandouk, Tagrid, et al., "The Antidiabetic Agent Pioglitazone Increases Expression of Glucose Transporters in 3T3-F442A Cells by Increasing Messenger Ribonucleic Acid Transcript Stability", Endocrinology, Vol. 133, No. 1, pp 352-359 (1993).							
V	9. Tafuri, Sherrie R., "Troglitazone Enhances Differentiation, Basal Glucose Uptake, and Glut 1 Protein Level 3T3-L1 Adipocytes", Endocrinology, Vol. 137, No. 11, pp 4706-4712 (1996).								
			•						
			······································						
	ļ <u>.</u>		=						
				·					
	ļ								
I				-					
									
				·					
									

EXAMINER: DATE CONSIDERED: 9/19/0>
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2131171 vl